Nymox Announces October 12 Symposium for Company's BPH Drug at American Urological Association Meeting
September 25 2017 - 10:30AM
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to
announce that an important large symposium and panel assessment of
the Company's new drug Fexapotide Triflutate will be held at the
October meeting of the American Urological Association, Northeast
Section. The October 12 symposium at the AUA meeting in Savannah
will include new data presentations from prominent Fexapotide
clinical trial urologists, and will feature panel assessments and
discussion of results from the U.S. Fexapotide trials
undertaken in 2009-2017. The Chairperson of the Symposium will be
James Bailen MD FACS of First Urology, Louisville KY.
Further details on the October 12 Symposium at
the AUA Meeting will be provided prior to the meeting.
Dr. Paul Averback, CEO of Nymox said, "The
upcoming Symposium at the AUA meeting October 12 will involve
highly experienced BPH investigators who participated in the trials
and who will present data and discuss results of the Fexapotide
Phase 3 clinical studies. Although unavoidably the earlier
Mid-Atlantic and South Central September and October meetings in
Florida were postponed due to emergency hurricane conditions, we
are very pleased that the October 12 AUA Northeast Section meeting
in Savannah will soon occur. Our management reiterates its
commitment to ramping up communication activities which are being
actively generated with the medical communities. This will be the
first of many important undertakings which will occur."
Nymox's lead drug Fexapotide has been in
development for over 10 years and has been tested by expert
clinical trial investigative teams in over 70 distinguished
clinical trial centers throughout the US, and has been found after
7 years of prospective placebo controlled double blind studies of
treatment of 995 U.S. men with prostate enlargement to not only
show clinically meaningful and durable relief of BPH symptoms, but
also to show a major reduction in the incidence of prostate cancer,
compared to placebo and compared to the known and expected normal
incidence of the disease. The same clinical program has also shown
in a long-term blinded placebo crossover group study an 82-95%
reduction in the number of these patients who required surgery
after they received crossover Fexapotide in the trial, as compared
to patients who did not receive Fexapotide but instead received
crossover conventional approved BPH treatments (p<.0001).
For more information please
contact info@nymox.com or 800-936-9669.
Forward Looking Statements
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Nymox, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including statements regarding the need for new options to
treat BPH and prostate cancer, the potential of Fexapotide to treat
BPH and prostate cancer and the estimated timing of further
developments for Fexapotide. Such forward-looking statements
involve substantial risks and uncertainties that could cause our
clinical development program, future results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in
the clinical drug development process, including the regulatory
approval process, the timing of Nymox's regulatory filings, Nymox's
substantial dependence on Fexapotide, Nymox's commercialization
plans and efforts and other matters that could affect the
availability or commercial potential of Fexapotide. Nymox
undertakes no obligation to update or revise any forwardlooking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of Nymox in general, see Nymox's current
and future reports filed with the U.S. Securities and Exchange
Commission, including its Annual Report on Form 20-F for the year
ended December 31, 2016, and its Quarterly Reports.
Contact:Paul AverbackNymox
Pharmaceutical Corporation800-93NYMOXwww.nymox.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Sep 2023 to Sep 2024